ProfileGDS5678 / 1434106_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 80% 84% 84% 78% 77% 81% 87% 82% 84% 82% 85% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8197582
GSM967853U87-EV human glioblastoma xenograft - Control 25.830381
GSM967854U87-EV human glioblastoma xenograft - Control 35.6222580
GSM967855U87-EV human glioblastoma xenograft - Control 46.3626984
GSM967856U87-EV human glioblastoma xenograft - Control 56.2047584
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.226178
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.088877
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8232281
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6140387
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0019282
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2176784
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.042682
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2914185
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.758381